NCM • United States
Supply Chain Position
Diversified companies with meaningful photonics exposure but not core supply chain thesis stocks
Charts by TradingView
Annual Overview
| Metric | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 0 | 433.03K▲ | 4.14M▲ | 23.85M▲ |
| Net Income | -4.95M | -16.29M▼ | -32.42M▼ | -175.09M▼ |
| EPS | — | -$0.49 | -$0.63▼ | -$2.11▼ |
| Free Cash Flow | -7.41M | -7.74M▼ | -26.37M▼ | -47.43M▼ |
| Capex | 4.47M | 2.33M▼ | 9.68M▲ | -9.65M▼ |
| Diluted Shares | — | 33.07M | 55.67M▲ | 83.01M▲ |
| Net Debt Issuance | -13.05K | 516.68K▲ | 400.31K▼ | 41.54M▲ |
| Net Equity Issuance | — | — | — | 320.3M |
| SBC | 2M | 8.74M▲ | 8.56M▼ | 16.02M▲ |
Estimate Revisions
Estimates stable
Earnings Track Record
Beat estimates 2 of last 8 quarters
Avg surprise: -134.4%
Growth
Ownership
Data from SEC 13F filings · Reported September 30, 2023
Earnings Calendar
Next earnings
No upcoming earnings date scheduled.
Last earnings
August 14, 2026
AI Summary
ASPI Isotopes Inc. positions itself as a diversified player with meaningful exposure to the photonics sector. While not entirely core to the photonics supply chain, ASPI is heavily involved in the supply of helium — a crucial element used in various photonics manufacturing processes. Their operations span multiple sectors, providing a hedge against volatility in singular market conditions.
ASPI Isotopes could capitalize on the growing demand for helium, especially given its recent acquisition of a South African plant with exceptionally high-grade helium. This asset could drive future revenue growth as helium continues to be in high demand for semiconductor manufacturing and other advanced technologies that rely on photonics. A significant improvement in gross margins to 38.6% from 32.1% points to efficient cost management strategies, particularly in their photonics-related divisions. If successfully leveraged, these factors could position ASPI to benefit from the broader shift in data center architectures that increasingly incorporate photonic technologies.
However, ASPI has severe financial weaknesses that cannot be overlooked. They have posted consistent net losses, with their latest fiscal year showing a $32.3 million shortfall. The debt to equity ratio is troubling at 1.18, suggesting potentially risky leverage that could hamper financial flexibility. The drop in market valuation, from a 52-week high of $14.49 to the current price of $4.29, reflects scepticism among investors. The company's inability to turn profitable or generate positive free cash flow underscores fundamental challenges that could deter future gains.
ASPI's financial trajectory reveals widening losses despite rising revenues. In FY2024, revenues increased roughly tenfold to $4.14 million, but this surge was shadowed by a net income loss of $32.3 million and a negative free cash flow exceeding $28 million. The gross margin improved to 38.6%, hinting at better cost control, but operating margins are alarmingly negative—indicative of significant operational inefficiency. Current financial metrics paint a picture of a company in the red, struggling to capitalize on its revenue increases sustainably.
ASPI appears overvalued based on conventional metrics. With a price-to-sales ratio of 64.0, the market is pricing in significant future growth and operational improvement not yet visible in current operations. Additionally, the company’s negative EV/EBITDA ratio signals an unhealthy financial position compared to peers like Kyocera and Panasonic, which boast more robust financials.
ASPI faces notable risks beyond typical market volatility. The company's customer concentration could be troubling; any loss of a major contract could disproportionately impact revenues and cash flow. Technology disruption presents another threat, especially if competitors develop more efficient, less helium-dependent processes. Moreover, geopolitical factors in South Africa, where their high-grade helium operations are located, could pose supply chain vulnerabilities or regulatory changes impacting helium export.
Investors should keep an eye on any announcements regarding increased production capability at their South African plant, which could materially impact revenues positively. Additionally, new contract announcements or expansions into other technology sectors reliant on photonics and helium could provide crucial lifelines to improving their financial health. Monitoring quarterly earnings reports for progress on achieving positive cash flows and a roadmap toward profitability will be critical over the next six months.
Last updated: April 4, 2026
ASPI Isotopes Inc. positions itself as a diversified player with meaningful exposure to the photonics sector. While not entirely core to the photonics supply chain, ASPI is heavily involved in the supply of helium — a crucial element used in various photonics manufacturing processes. Their operations span multiple sectors, providing a hedge against volatility in singular market conditions.
ASPI Isotopes could capitalize on the growing demand for helium, especially given its recent acquisition of a South African plant with exceptionally high-grade helium. This asset could drive future revenue growth as helium continues to be in high demand for semiconductor manufacturing and other advanced technologies that rely on photonics. A significant improvement in gross margins to 38.6% from 32.1% points to efficient cost management strategies, particularly in their photonics-related divisions. If successfully leveraged, these factors could position ASPI to benefit from the broader shift in data center architectures that increasingly incorporate photonic technologies.
However, ASPI has severe financial weaknesses that cannot be overlooked. They have posted consistent net losses, with their latest fiscal year showing a $32.3 million shortfall. The debt to equity ratio is troubling at 1.18, suggesting potentially risky leverage that could hamper financial flexibility. The drop in market valuation, from a 52-week high of $14.49 to the current price of $4.29, reflects scepticism among investors. The company's inability to turn profitable or generate positive free cash flow underscores fundamental challenges that could deter future gains.
ASPI's financial trajectory reveals widening losses despite rising revenues. In FY2024, revenues increased roughly tenfold to $4.14 million, but this surge was shadowed by a net income loss of $32.3 million and a negative free cash flow exceeding $28 million. The gross margin improved to 38.6%, hinting at better cost control, but operating margins are alarmingly negative—indicative of significant operational inefficiency. Current financial metrics paint a picture of a company in the red, struggling to capitalize on its revenue increases sustainably.
ASPI appears overvalued based on conventional metrics. With a price-to-sales ratio of 64.0, the market is pricing in significant future growth and operational improvement not yet visible in current operations. Additionally, the company’s negative EV/EBITDA ratio signals an unhealthy financial position compared to peers like Kyocera and Panasonic, which boast more robust financials.
ASPI faces notable risks beyond typical market volatility. The company's customer concentration could be troubling; any loss of a major contract could disproportionately impact revenues and cash flow. Technology disruption presents another threat, especially if competitors develop more efficient, less helium-dependent processes. Moreover, geopolitical factors in South Africa, where their high-grade helium operations are located, could pose supply chain vulnerabilities or regulatory changes impacting helium export.
Investors should keep an eye on any announcements regarding increased production capability at their South African plant, which could materially impact revenues positively. Additionally, new contract announcements or expansions into other technology sectors reliant on photonics and helium could provide crucial lifelines to improving their financial health. Monitoring quarterly earnings reports for progress on achieving positive cash flows and a roadmap toward profitability will be critical over the next six months.
ASPI Isotopes Inc. positions itself as a diversified player with meaningful exposure to the photonics sector. While not entirely core to the photonics supply chain, ASPI is heavily involved in the supply of helium — a crucial element used in various photonics manufacturing processes.
ASP Isotopes Inc. is in the Adjacent / Diversified layer of the photonics supply chain. Diversified companies with meaningful photonics exposure but not core supply chain thesis stocks
In FY2025, ASP Isotopes Inc. reported a net loss of $175.09M.
Companies in the same supply chain layer as ASP Isotopes Inc. include Aeva Technologies, Inc., Draganfly Inc., GL Tech Co.,Ltd, Han's Laser Technology Industry Group Co., Ltd., and Himax Technologies, Inc..
No upcoming earnings date is currently available. ASP Isotopes Inc. last reported on August 14, 2026.
Analysis updated April 2026
ASP Isotopes (ASPI) drew attention this week after announcing that Tetra4, a Renergen subsidiary, has completed commissioning and reached stable liquid helium production at South Africa’s Virginia Gas Project. The helium milestone comes after a sharp pullback in ASP Isotopes’ shares, which closed at US$1.72 following a 1-day share price return that declined 9.95% and a 30-day share price return that fell 39.65%. Despite a 3-year total shareholder return of 52.21%, momentum has cooled...
ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its Small Stocks, Big Money™ television program is now airing on ...
ASP Isotopes (NASDAQ:ASPI) executives outlined plans to create a publicly listed helium and liquefied natural gas platform through Noble Africa, emphasizing Renergen’s South African helium resource, expected near-term production milestones and the proposed merger with ENDRA Life Sciences. Paul Mann
In July 2026, ASP Isotopes Inc. filed a shelf registration to offer 23,160,682 shares of common stock, with an aggregate value of US$106.08 million. We will now examine how ASP Isotopes’ broader investment narrative is shaping up.
ASP Isotopes (ASPI) has filed a shelf registration for up to US$106.1 million of common stock, covering 23,160,682 shares.
QumulusAI's common shares have begun trading on the Nasdaq Global Market under the ticker symbol "QM
Exchange reduces QLE’s outstanding convertible notes by approximately 50% as QLE continues to pursue a public listing as a separate companyDALLAS, July 15, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASPI", the "Company" or “we”) today announced that ASPI and Quantum Leap Energy LLC ("QLE"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, have entered into separat
ORLANDO, FL / ACCESS Newswire / June 26, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and ASP Isotopes, Inc. (Nasdaq:ASPI) on the RedChip Small Stocks, Big Money™show, a sponsored program on ...
DALLAS & ANN ARBOR, Mich., June 25, 2026--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," "ASPI" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or "NDRA"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that ASP Isotopes’ wholly-owned subsi